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Background. Maternal alloantibodies against HPA-1a can cross placenta, opsonize foetal platelets, and induce neonatal alloimmune
thrombocytopenia (NAIT). In a study of 100, 448 pregnant women in Norway during 1995–2004, 10.6% of HPA-1a negative
women had detectable anti-HPA-1a antibodies. Design and Methods. A possible correlation between the maternal ABO blood
group phenotype, or underlying genotype, and severe thrombocytopenia in the newborn was investigated. Results. We observed
that immunized women with blood group O had a lower risk of having a child with severe NAIT than women with group A; 20%
with blood group O gave birth to children with severe NAIT, compared to 47% among the blood group A mothers (relative risk
0.43; 95% CI 0.25–0.75). Conclusion. The risk of severe neonatal alloimmune thrombocytopenia due to anti-HPA-1a antibodies is
correlated to maternal ABO types, and this study indicates that the observation is due to genetic properties on the maternal side.
1. Introduction
Foetal-maternal incompatibility in the human platelet anti-
gen (HPA)-1 alloantigen system is the most common
underlying cause of neonatal alloimmune thrombocytope-
nia (NAIT), a condition where maternal alloantibodies
opsonize foetal platelets during pregnancy and reduce their
survival in circulation. The incompatibility is based on a
single-nucleotide polymorphism (SNP) which results in a
leucine/proline substitution at residue 33 in the β3 integrin
that constitutes membrane glycoprotein β3 [GPIIIa] present
on platelets in complex with αIIb integrin [GPIIb] [1]. On
platelets, the αIIbβ3 [GPIIb/IIIa] is also the major carrier of
blood group A antigen [2].
About 10% of HPA-1a negative women who have been
pregnant with an HPA-1-incompatible child have detectable
HPA-1a antibodies [3]. In several studies, a correlation
between maternal antibody level and the severity of throm-
bocytopenia in the newborn has been shown [4–6]. The
alloimmunization is strongly associated with the HLA-
DRB3∗01 : 01 allele [3, 7, 8]; however, only about 30% of
the women with this HLA antigen are immunized. Except
for the incompatibility in platelet antigen and the association
to HLA, other factors which may influence the immune
response to HPA-1a have not been identified.
In the present study, we have examined the maternal
ABO blood groups and frequency of HPA-1a-immunization
of the women identified in the large prospective screening
and intervention study carried out in Norway from 1995
to 2004. We included 152 HPA-1a-immunized women, 146
of whom had altogether 158 HPA-1-incompatible pregnan-
cies in the screening study. The ABO distribution among
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immunized women was investigated, and the maternal ABO
phenotype and ABO genotype was correlated to the severity
of thrombocytopenia of the newborn.
2. Materials and Methods
2.1. Patients. Pregnant women were recruited for HPA-1
allotyping from three regions in Norway between December,
1995 and March, 2004 [3]. Samples for routine Rh(D) typing
were also used for determining HPA-1 allotype by flow
cytometry (anti-CD61 mAb), enzyme-linked immunosor-
bent assay (ELISA), or polymerase chain reaction (PCR) as
previously described [9]. A total of 100,448 pregnant women
were typed for the platelet antigen HPA-1a, and 2,111 of
those were HPA-1a negative (2.1%). Of these, 1,990 were
further tested, and anti-HPA-1a antibodies were detected
in 154 women during the pregnancy. In total, 146 of these
immunized women underwent 158 HPA-1a-incompatible
pregnancies. ABO blood group typing was performed by
conventional technique. Genomic typing of HPA-1 (ITGB3;
rs5918 in dbSNP) and ABO in the neonates was performed in
samples from cord blood or buccal swabs. For the newborns,
the ABO genotype was used to predict the ABO blood group.
In this context, we have defined ABO incompatibility only
as an A1 phenotype in the newborn, in blood group O
mothers, because individuals with A2, and the majority of
individuals with B phenotype, express only low levels of
corresponding antigens on the surface of platelets [2, 10–12].
Thrombocytopenia was defined as a platelet count ≤150 ×
109/L, and severe thrombocytopenia less than 50 × 109/L
measured in cord blood and/or capillary blood at birth.
Detection of anti-HPA-1a IgG antibodies was performed by
flow cytometry and quantified with monoclonal antibody
immobilization of platelet antigen assay (MAIPA) [3], by
using the anti-CD61 monoclonal antibody clone Y2/51
(Dako, Glostrup, Denmark) for immobilisation of platelet
glycoproteins. Women were tested at several time points
during the pregnancy, and those with a positive antibody
test at any time during the pregnancy were characterized
as immunized. Nineteen women were primary immunized
during the studied pregnancy, 13 of these were primigravida.
All others may have been immunized in connection with
a prior pregnancy. Prior affected pregnancies were not
excluded as a cause of severe NAIT. The NAIT diagnosis
was based on maternal anti-HPA-1a antibodies and HPA-1a
antigen incompatibility. Other possible reasons for thrombo-
cytopenia (infection, maternal ITP, etc.) were not registered.
Informed consent was provided in accordance with the
declaration of Helsinki. The study was approved by the
Regional Committee for Medical Research Ethics, North
Norway (approval no. P-REK V 13/1995).
2.2. ABO Genotyping. ABO genotyping was performed by
PCR-RFLP analysis to detect six major alleles, A1, A2, B,
O1/O1v, and O2 (also known as A101/A201/B101/O01/O02/
O03) according to the nomenclature used by the Blood
Group Antigen Gene Mutation Database, dbRBC [13], and
further discrimination between the common O1 and O1v
alleles [O01/O02] was performed using primers and reaction
conditions as described by Olsson and Chester [14, 15]
with some modifications: HotStarTaq polymerase 5 U/μL
(QIAGEN, Hilden, Germany) was used with the following
cycling programs for both analyses: 95◦C 15 min, 10 cycles of
94◦C for 10 seconds, 63◦C for 30 seconds and 72◦C for 30
seconds followed by 25 cycles of 94◦C for 10 seconds, 61◦C
for 30 seconds and 72◦C for 30 seconds for samples with
100 ng DNA template. For samples with ∼25 ng template
and <10 ng DNA template, 1 and 2 extra cycles at each
of the annealing temperatures was performed, respectively.
Subsequently, digestion with endonucleases and qualitative
analyses of product were performed [14, 15]. Ambiguous
results were confirmed with selected primer sets from a
recently published PCR-ASP method for ABO genotyping
[16]. For simplicity, only one terminology, dbRBC, will be
used throughout this paper. Genotypes are written as X/X.
2.3. Statistical Analysis. Standard statistical calculations as
mean, relative risk, Chi-square test, analysis of variance
with Bonferroni’s test as post hoc analysis, and plots
were performed with computer software SPSS for windows
(Statistical Package for the Social Sciences, Version 16.0 SPSS
Inc., Chicago, Ill, USA). P < 0.05 was considered significant.
3. Results
3.1. The ABO Phenotype Distribution of the Immunized
Mothers. The ABO phenotype distribution among 154 HPA-
1a immunized women was similar to the distribution of the
general Norwegian population [17] adjusted to statistics for
2005 (data not shown), indicating that the maternal ABO
type does not influence the risk of HPA-1a immunization.
3.2. Maternal ABO Blood Group and Risk of Severe NAIT.
In 158 HPA-1-incompatible pregnancies with 83 cases of
NAIT, there were 54 cases of severe NAIT. The maternal
ABO phenotypes were compared to the platelet count in
their neonates (Table 1); 46.6% of the immunized women
with blood group A gave birth to children with severe
NAIT, compared to 20.0% among the immunized mothers
with blood group O. The relative risk of NAIT (platelet
count ≤150 × 109/L) in the neonates of HPA-1a immunized
women with blood group O as compared to blood group
A was 0.67 (95% CI 0.48–0.94), whereas the relative risk of
severe NAIT (platelet count <50 × 109/L) in the neonates
of HPA-1a immunized women with blood group O was 0.43
(95% CI 0.25–0.75) as compared to the neonates of women
with blood group A. However, the frequency of moderate
NAIT (platelet count 50–150 × 109/L) was not lower among
the blood group O mothers. 91% of the immunized women
carried the HLA-DRB3∗01 : 01 allele. There were no cases of
severe NAIT among HLA-DRB3∗01 : 01-negative mothers.
3.3. ABO Incompatibilities between Mothers and Newborns.
To investigate whether the ABO incompatibility between
mother and foetus could explain the difference in the
frequency of severe NAIT, newborns were ABO genotyped as
basis for the prediction of their ABO phenotype. One hun-
dred and thirty out of 146 newborns were ABO genotyped
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Table 1: The maternal ABO type distribution in the pregnancies compared to the severity of NAIT.
Maternal ABO
type
Numbers of newborns with platelet count
<50 × 109/L
(% within ABO type; 95% CI)
Numbers of newborns with platelet
count 50–150 × 109/L
Numbers of newborns with
platelet count >150 × 109/L P value
†
A 34 (46.6; 0.36–0.58) 13 26 0.005
O 12 (20.0; 0.12–0.32) 14 34
B 7 (38.9; 0.20–0.61) 1 10
AB 1 (14.3; 0.03–0.51) 1 5
Total 54 29 75
Relative risk of NAIT was 0.67 (95% CI 0.48–0.94) in neonates born of women with blood group O versus blood group A.
Relative risk of severe NAIT was 0.43 (95% CI 0.25–0.75) in neonates born of women with blood group O versus blood group A.
†Chi-square test (two-sided) for frequencies of NAIT and severe NAIT in blood group O compared to blood group A.
(restricted by lack of material). For ABO-incompatibility
studies, thus only 52 of 60 blood group O mother-child
pairings could be included. The fifty-two mothers with blood
group O gave birth to 16 A-incompatible (blood group A1)
and 36 compatible (sixteen blood group O, one B, and five
A2) children. Four of the 16 A-incompatible pregnancies
resulted in a newborn with severe thrombocytopenia com-
pared to 6 of the 36 ABO-compatible pregnancies. This
indicates that ABO incompatibility is not the underlying
cause of the observed phenomenon reported in the present
study.
3.4. The ABO Genotype of the Mothers and Platelet Counts in
the Newborn. The ABO genotype of 143 HPA-1a-immunized
women who gave birth to 155 HPA-1a-positive neonates
was determined (data not shown). The overall O allele
frequencies among the immunized women were O01 0.56,
O02 0.42, and O03 0.02. Individuals with blood groups A, B,
and O were further subgrouped based on genotyping, and
thus, the frequencies of newborns with severe NAIT within
each subgroup were compared. The cases with maternal
blood group AB were excluded for further analysis due to the
low number of individuals. Analysis of the platelet counts in
newborns of mothers with different ABO genotypes revealed
that the frequency of newborns with severe NAIT differed
(Pearson Chi-square P = 0.0036) among the maternal ABO
genotype groups.
Among blood group A mothers, the frequency of new-
borns with severe NAIT was 42% in pregnancies where the
mother carried only one A allele (A101 or A201), compared
to 69% where mothers carried two A alleles (relative risk
0.61; 95% CI 0.38–0.98). In pregnancies where the mother
had blood group O, the frequency of newborns with severe
NAIT was 9%, where the mother did not carry any O02
allele, compared to 27% where the mother carried one or two
O02 alleles; however, this did not reach statistical significance
(relative risk 0.33 NS P = 0.13).
Platelet counts in newborns of mothers with blood
group A and O are plotted in Figure 1. The mean antibody
levels between these groups were not significantly different:
11.6 IU/mL for blood group A mothers, 1.8 IU/mL for
O02-negative blood group O mothers, and 11.1 IU/mL for
O02-positive blood group O mothers (P = 0.18 one-way

































Figure 1: The platelet count at delivery in HPA-1a-positive new-
borns was grouped according to maternal ABO type (A or O).
Platelet count ≤150 × 109/L (dashed line) is defined as NAIT and
<50 × 109/L (dotted line) as severe NAIT. The mean platelet counts
in the three groups are indicated, with error bars representing
95% CI. Mean platelet counts are significantly different (P <
0.019, one-way ANOVA). The mean antibody levels between these
groups are not significantly different: 11.6 IU/mL for blood group A
mothers, 11.1 IU/mL for O02-positive blood group O mothers, and
1.8 IU/mL O02-negative blood group O mothers.
antibody level and platelet count in the newborn for these
cases was described in Killie et al. [6].
Among the NAIT cases, defined as platelet count≤150 ×
109/L, the mean platelet count in newborns of homozygous
O01/O01 mothers was higher (83.2 × 109/L) than in the
newborns with O02-positive mothers with blood group O
(43.7 × 109/L) or in newborns of women with blood group
A (46.1 × 109/L) (Table 2). Together, these data support
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Table 2: Platelet counts in the newborns with NAIT.






Genotype O01/O01 9 86 83.2 (56.9–109.6)
Genotypes O01/O02
and O02/O02
17 21 43.7 (22.7–64.7) 0.043†
Blood group A 47 31 46.1 (35.0–57.2) 0.028†
∗
Total number of pregnancies resulting in a newborn with NAIT (platelet count ≤150) was 83. DNA for genotyping was available for 68 women with blood
group O or A, and they had altogether 73 HPA-1-incompatible pregnancies.
†Comparison with platelet counts in children born of women with the genotype O01/O01.
our hypothesis that there are genetic properties among the
immunized women influencing the risk of severe NAIT in
the newborn.
4. Discussion
The ABO phenotype distribution among the HPA-1a immu-
nized women is similar to the distribution in the Norwegian
population, indicating that the generation of an immune
response with antibody synthesis is independent of the ABO
blood group of the mother. However, we observed that
whereas only 20% of pregnancies among the immunized
women with blood group O resulted in severe NAIT in
the newborn, 47% of the immunized women with blood
group A had newborns with severe thrombocytopenia.
A recent retrospective study by Bertrand et al. did not
find any significant correlation between the severity of the
thrombocytopenia and the ABO genotype [18]. As these
authors propose, the discrepancy between Bertrands’s and
our study may be due the retrospective/prospective nature of
the studies. We found no indications that the low frequency
of severe NAIT in the children of women with blood group
O was due to ABO incompatibility between mother and
foetus. Additional measurements of maternal anti-RBC IgG
antibody in the women with blood group O could have
given further information of any influence of potential
antibodies directed against the A antigen carried by αIIb
on platelets. Another hypothesis that could explain the
lower frequency of newborns with severe NAIT among the
immunized mothers with blood group O, compared to blood
group A, is that the ABO gene is located close to a gene
encoding an immunoregulatory factor with polymorphic
variants. In order to approach this question, we compared
NAIT to ABO genotypes. The allelic differences in the gene
encoding the A/B glycosyltransferases are defined by SNPs
that changes the amino acid sequence of the enzyme and
thereby its glycosylating properties. The A101, A201, B101,
O01, O02, and O03 alleles all produce transcripts (although
A transcripts are virtually undetectable in peripheral blood)
[19, 20], but the O01 and O02 transcripts both contain a shift
in the reading frames that will severely truncate any resulting
protein and leave it without enzymatic activity [21]. It is still
unclear if these short nonfunctional proteins are expressed at
all although it has been suggested [22].
The ABO genotype frequencies in the Norwegian popu-
lation are not known, but the O allele frequencies observed
in immunized women are similar to the frequencies reported
for a Swedish population [15], where the O02 constitutes
about 40% of all O alleles and O03 allele is infrequent. This
further shows that the generation of an immune response
to HPA-1a is independent of ABO blood groups. However,
when it comes to development of NAIT, the different risks of
severe thrombocytopenia observed in genetic subgroups of
blood group A support the hypothesis that a genetic linkage
may be involved, rather than the ABO phenotype itself even
though the mechanism is still not understood. Although the
differences in the O02-positive and O02-negative subgroups
of blood group O do not reach statistical significance, an
interesting trend is observed.
Phylogenetic analyses of the ABO locus have shown
that the O02 probably is an ancient allelic lineage at the
ABO locus, separate from the A101 and O01 alleles [23].
Therefore, it is interesting to subdivide the blood group O
women according to their genotype. The 9q34 chromosomal
region, where the ABO gene is located [24], contains several
loci encoding immune response regulating genes. There is
obviously no genetic linkage between the ABO [9q34] and
ITGB3 [17q21] loci. The association of the ABO type to the
development of severe NAIT could be due to a potential
linkage to one or more gene(s) encoding regulatory factors.
Further investigation has to be conducted to find out whether
such factors are linked to the ABO locus in a way that can
explain our observation.
5. Conclusions
The development of severe NAIT in newborns is caused
by transfer of platelet-reactive antibodies during pregnancy;
however, several biological factors likely play a role in
the immune response mechanism. In the present study,
with data from a prospective NAIT study, we showed that
the risk of severe NAIT due to anti-HPA-1a antibodies is
correlated to maternal ABO types. The results indicate that
there are genetic properties related to the maternal ABO
genotype that influence the immune response that cause
severe thrombocytopenia in the newborn of anti-HPA-1a
immunized mothers.
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